[go: up one dir, main page]

BR9713314A - Inibidores da enzima de conversão interleucina-1beta de ácido aspártico substituìdo com sulfonamida - Google Patents

Inibidores da enzima de conversão interleucina-1beta de ácido aspártico substituìdo com sulfonamida

Info

Publication number
BR9713314A
BR9713314A BR9713314-0A BR9713314A BR9713314A BR 9713314 A BR9713314 A BR 9713314A BR 9713314 A BR9713314 A BR 9713314A BR 9713314 A BR9713314 A BR 9713314A
Authority
BR
Brazil
Prior art keywords
inhibitors
pct
1beta
sulfonamide
interleukin
Prior art date
Application number
BR9713314-0A
Other languages
English (en)
Inventor
Hamish John Allen
Kenneth Dale Brady
William Glen Harter
Elizabeth Ann Lunney
Mark Stephen Plummer
Tomi Sawyer
Aurash Shahripour
Nigel Walker
Original Assignee
Warner Lambert Co
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co, Basf Ag filed Critical Warner Lambert Co
Publication of BR9713314A publication Critical patent/BR9713314A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/12—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/67—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfonamide groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)

Abstract

Patente de Invenção:<B>"INIBIDORES DE ENZIMA DE CONVERSãO INTERLEUCINA-1BETA DE áCIDO ASPáRTICO SUBSTITUìDO COM SULFONAMIDA'<D>. A presente invenção refere-se aos compostos que são inibidores da enzima de conversão interleucina-1<225> que possui a fórmula (I, II ou III). Esta invenção também refere-se a um método de tratamento de apoplexia, doenças inflamatórias, choque séptico, ferimento de reperfusão, doença de Alzheimer, Disenteria bacilar, e uma composição farmaceuticamente aceitável que contenha um composto que é um inibidor de enzima de conversão interleucina-1<225>.
BR9713314-0A 1996-10-11 1997-10-09 Inibidores da enzima de conversão interleucina-1beta de ácido aspártico substituìdo com sulfonamida BR9713314A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2832396P 1996-10-11 1996-10-11
PCT/US1997/018406 WO1998016504A2 (en) 1996-10-11 1997-10-09 SULFONAMIDE SUBSTITUTED ASPARTIC ACID INTERLEUKIN-1β CONVERTING ENZYME INHIBITORS

Publications (1)

Publication Number Publication Date
BR9713314A true BR9713314A (pt) 2000-01-25

Family

ID=21842812

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9713314-0A BR9713314A (pt) 1996-10-11 1997-10-09 Inibidores da enzima de conversão interleucina-1beta de ácido aspártico substituìdo com sulfonamida

Country Status (14)

Country Link
US (1) US6083981A (pt)
EP (1) EP0932600B1 (pt)
JP (1) JP2001502330A (pt)
KR (1) KR20000049050A (pt)
AT (1) ATE317381T1 (pt)
AU (1) AU742746B2 (pt)
BR (1) BR9713314A (pt)
CA (1) CA2268103A1 (pt)
DE (1) DE69735230D1 (pt)
IL (1) IL129124A0 (pt)
NO (1) NO315042B1 (pt)
NZ (1) NZ334887A (pt)
PL (1) PL332704A1 (pt)
WO (1) WO1998016504A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0116063A (pt) 2000-12-13 2004-08-03 Wyeth Corp Inibidores de sulfonamida heterocìclica da produção de beta amilóide e seus usos
US6875765B2 (en) 2001-05-10 2005-04-05 Warner-Lambert Company Arylsulfonamide ethers, and methods of use thereof
IL158866A0 (en) * 2001-05-16 2004-05-12 Yeda Res & Dev Use of il-18 inhibitors for the treatment or prevention of sepsis
JP2007528405A (ja) * 2004-03-11 2007-10-11 イーラン ファーマスーティカルズ、インコーポレイテッド Ｎ−置換ベンゼンスルホンアミド
CN1980648A (zh) 2004-05-15 2007-06-13 沃泰克斯药物股份有限公司 使用ice抑制剂治疗癫痫发作
WO2005110450A1 (ja) * 2004-05-17 2005-11-24 Keio University 医薬組成物及び治療方法
US7531570B2 (en) 2004-05-27 2009-05-12 Vertex Pharmaceuticals Incorporated Treatment of diseases using ICE inhibitors
EP2532643A1 (en) 2007-06-08 2012-12-12 MannKind Corporation IRE-1A Inhibitors
MY148484A (en) 2007-08-03 2013-04-30 Sanofi Aventis Caspase imaging probes
WO2010042652A2 (en) 2008-10-08 2010-04-15 Amira Pharmaceuticals, Inc. Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
EP2635907A4 (en) 2010-11-05 2014-04-16 Univ Brandeis ICE-COLDED ALPHA SYNNUCLEINE A BIOMARKERS
US9956260B1 (en) 2011-07-22 2018-05-01 The J. David Gladstone Institutes Treatment of HIV-1 infection and AIDS
EP2848696A1 (en) 2013-09-13 2015-03-18 Sanofi-Aventis Deutschland GmbH Caspase-1 imaging probes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) * 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
DE4102024A1 (de) * 1991-01-24 1992-07-30 Thomae Gmbh Dr K Biphenylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
EP0519748B1 (en) * 1991-06-21 1998-09-02 Merck & Co. Inc. Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme
GB9200420D0 (en) * 1992-01-09 1992-02-26 James Black Foundation The Lim Amino acid derivatives
DK0752987T3 (da) * 1994-03-31 2004-03-15 Vertex Pharma Pyrimidinylderivater som interleukininhibitorer
US5552400A (en) * 1994-06-08 1996-09-03 Sterling Winthrop Inc. Fused-bicyclic lactams as interleukin-1β converting enzyme inhibitors
US5756466A (en) * 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5716929A (en) * 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme

Also Published As

Publication number Publication date
EP0932600A2 (en) 1999-08-04
ATE317381T1 (de) 2006-02-15
WO1998016504A2 (en) 1998-04-23
NZ334887A (en) 2000-09-29
WO1998016504A3 (en) 1998-06-25
IL129124A0 (en) 2000-02-17
PL332704A1 (en) 1999-09-27
NO315042B1 (no) 2003-06-30
DE69735230D1 (de) 2006-04-20
CA2268103A1 (en) 1998-04-23
EP0932600B1 (en) 2006-02-08
JP2001502330A (ja) 2001-02-20
NO991678D0 (no) 1999-04-09
AU4817297A (en) 1998-05-11
NO991678L (no) 1999-04-12
AU742746B2 (en) 2002-01-10
US6083981A (en) 2000-07-04
KR20000049050A (ko) 2000-07-25

Similar Documents

Publication Publication Date Title
NO991674L (no) Interleukin-1&lt;Beta&gt;omdannelsesenzym-inhibitor-sulfonamider
PT1049703E (pt) Aldeido do acido n-¬2-(5-benziloxicarbonilamino-6-oxo-2-(4-fluorofenil)-1,6-di-hidro-1-pirimidinil)acetoxil|-l-aspartico como inibidor da enzima de conversao da interleucina-1beta in vivo
BR9712530A (pt) Inibidores de ésteres de asparato de enzima de conversão de interleucina-1beta
ATE240103T1 (de) Intermediaires des produits definitifs de glycosylation avancee et inhibition des produits age post-amadori
BR9713314A (pt) Inibidores da enzima de conversão interleucina-1beta de ácido aspártico substituìdo com sulfonamida
DE69935153D1 (de) Benzamide als kaliumkanal-inhibitoren
ID22042A (id) Benzonaftiridin sebagai pengobatan cabang tenggorokan
EP1443935A4 (en) TREATMENT OF INFECTIOUS DISEASES WITH INTERLEUKIN-1 BETA CONVERTING ENZYME (ICE) / CED-3 INHIBITORS
EA200000741A1 (ru) Новые производные дигидроксигексановой кислоты
YU67900A (sh) Sukcinamidni inhibitori interleukin-1beta konvertujućeg enzima
BR9503572A (pt) Composto composiçao farmaceutica e método de tratamento ou prevençao de uma doença
CA2266759A1 (en) 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
EE200000550A (et) Desinfitseeriv kompositsioon
EA200000204A1 (ru) Производные пирролопирролона в качестве ингибиторов эластазы нейтрофилов
MXPA03010179A (es) Eteres de arilsulfonamida y metodos de uso de los mismos.
WO2001091796A8 (en) Methods, compounds and compositions for treating gout
FI974444A0 (fi) N-hydroksiureayhdisteitä anti-inflammatorisina aineina
ES2074946A1 (es) Nuevos compuestos derivados de la 1,2-etanodiamina-n,n,n&#39;,n&#39;-tetrasustituida.
BR0015482A (pt) Antagonistas de difenil leucotrieno de heterociclo substituìdo
IT1294932B1 (it) Uso di 2-amminotetraline-6,7 sostituite per la preparazione di composizioni farmaceutiche atte al trattamento di patologie
BR9612000A (pt) Naftil glioxamidas como inibidores de spla; &#39;

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements